These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38655598)

  • 1. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
    Silvestro M; Orologio I; Tessitore A; Trojsi F; Tedeschi G; Russo A
    Expert Rev Neurother; 2024 Jun; 24(6):555-564. PubMed ID: 38655598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
    Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
    Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroergotamine nasal spray for the acute treatment of migraine.
    Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N
    Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
    Lipton RB; Albrecht D; Bermudez M; Hu J; Hussey E; Levy J
    Headache; 2024 Mar; 64(3):266-275. PubMed ID: 38413540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
    Gallagher RM
    Arch Neurol; 1996 Dec; 53(12):1285-91. PubMed ID: 8970458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
    Silberstein SD; Shrewsbury SB; Hoekman J
    Headache; 2020 Jan; 60(1):40-57. PubMed ID: 31737909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
    Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E
    Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.
    Cooper W; Ray S; Aurora SK; Shrewsbury SB; Fuller C; Davies G; Hoekman J
    J Aerosol Med Pulm Drug Deliv; 2022 Dec; 35(6):321-332. PubMed ID: 36108289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
    Silberstein SD; Kori SH
    CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new dihydroergotamine nasal spray (Trudhesa) for migraine.
    Med Lett Drugs Ther; 2021 Dec; 63(1640):204-207. PubMed ID: 35100240
    [No Abstract]   [Full Text] [Related]  

  • 15. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
    Tulunay FC; Karan O; Aydin N; Culcuoglu A; Guvener A
    Cephalalgia; 1987 Jun; 7(2):131-3. PubMed ID: 3301001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.